Bupropion (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bupropion" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

25nih.gov

4^th place

13^th place

21doi.org

2^nd place

4^th place

6web.archive.org

1^st place

6archive.org

6^th place

2^nd place

4books.google.com

3^rd place

6^th place

3drugs.com

399^th place

480^th place

2fda.gov

447^th place

792^nd place

1medicines.org.uk

3,823^rd place

9,839^th place

1tga.gov.au

3,984^th place

4,575^th place

1google.ca

838^th place

272^nd place

1uspto.gov

1,459^th place

2,093^rd place

146.154

low place

1medicaid.gov

low place

1clincalc.com

3,912^th place

low place

1worldcat.org

5^th place

7^th place

1biospace.com

low place

1gsk.com

low place

1harvard.edu

18^th place

44^th place

1emedexpert.com

low place

1medscape.com

719^th place

1,112^th place

1nytimes.com

7^th place

35^th place

1garant.ru

1,937^th place

8,068^th place

46.154

82.77.46.154

World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83" (PDF). WHO Drug Information. 14 (2). Diarsipkan dari versi asli (PDF) tanggal 1 February 2010. Diakses tanggal 22 June 2009.

archive.org

Feinberg SS (2004). "Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication". J Clin Psychiatry. 65 (11): 1520–4. doi:10.4088/jcp.v65n1113. PMID 15554766.
Horst WD, Preskorn SH (December 1998). "Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion". J Affect Disord. 51 (3): 237–54. doi:10.1016/S0165-0327(98)00222-5. PMID 10333980.
Ascher JA, Cole JO, Colin JN, et al. (September 1995). "Bupropion: a review of its mechanism of antidepressant activity". J Clin Psychiatry. 56 (9): 395–401. PMID 7665537.
Ascher, JA; Cole, JO; Colin, JN; Feighner, JP; Ferris, RM; Fibiger, HC; Golden, RN; Martin, P; Potter, WZ; Richelson, E (September 1995). "Bupropion: a review of its mechanism of antidepressant activity". The Journal of Clinical Psychiatry. 56 (9): 395–401. PMID 7665537.
Preskorn SH (1991). "Should bupropion dosage be adjusted based upon therapeutic drug monitoring?". Psychopharmacol Bull. 27 (4): 637–43. PMID 1813908.
Perrine DM, Ross JT, Nervi SJ, Zimmerman RH (2000). "A Short, One-Pot Synthesis of Bupropion (Zyban, Wellbutrin)". Journal of Chemical Education. 77 (11): 1479. Bibcode:2000JChEd..77.1479P. doi:10.1021/ed077p1479.

biospace.com

"GlaxoSmithKline (GSK) Reviews Novel Therapeutics For CNS Disorders And Confirms Strong Pipeline Momentum" (Siaran pers). PRNewswire. 23 November 2004. Diarsipkan dari versi asli tanggal 28 September 2007. Diakses tanggal 18 August 2007. "Salinan arsip". Diarsipkan dari versi asli tanggal 2017-03-20. Diakses tanggal 2019-07-07.

books.google.com

Dwoskin, Linda P. (29 Januari 2014). Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Elsevier Science. hlm. 177–216. ISBN 978-0-12-420177-4.
Tasman, Allan, Kay, Jerald, Lieberman, Jeffrey A., First, Michael B., Maj, Mario (11 Oktober 2011). Psychiatry. John Wiley & Sons. ISBN 978-1-119-96540-4.
Lemke, Thomas L., Williams, David A. (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. hlm. 611–613. ISBN 978-1-60913-345-0.
Labbate, Lawrence A., Fava, Maurizio, Rosenbaum, Jerrold F., Arana, George W. (28 March 2012). Handbook of Psychiatric Drug Therapy. Lippincott Williams & Wilkins. hlm. 64–. ISBN 978-1-4511-5307-1.

clincalc.com

"The Top 300 of 2019". clincalc.com. Diakses tanggal 22 Desember 2018.

doi.org

Zhu, A. Z. X.; Zhou, Q.; Cox, L. S.; Ahluwalia, J. S.; Benowitz, N. L.; Tyndale, R. F. (3 September 2014). "Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes". Drug Metabolism and Disposition. 42 (11): 1971–1977. doi:10.1124/dmd.114.060285. PMC 4201132 . PMID 25187485.
Schwasinger-Schmidt, TE; Macaluso, M (8 September 2018). "Other Antidepressants". Handbook of Experimental Pharmacology. doi:10.1007/164_2018_167. PMID 30194544.
Fava M, Rush AJ, Thase ME, et al. (2005). "15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL". Prim Care Companion J Clin Psychiatry. 7 (3): 106–13. doi:10.4088/pcc.v07n0305. PMC 1163271 . PMID 16027765.
Jefferson JW, Pradko JF, Muir KT (November 2005). "Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations". Clin Ther. 27 (11): 1685–95. doi:10.1016/j.clinthera.2005.11.011. PMID 16368442.
Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT (2006). "Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent". CNS Drug Rev. 12 (3–4): 178–207. doi:10.1111/j.1527-3458.2006.00178.x. PMID 17227286.
Fidel Vila-Rodriguez, Fidel; Dobek, Christine E; Blumberger, Daniel M; Downar, Jonathan; Daskalakis, Zafiris J (2015). "Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion". Neuropsychiatric Disease and Treatment. 11: 2975–87. doi:10.2147/NDT.S91126. ISSN 1178-2021. PMC 4670017 . PMID 26664122.
Feinberg SS (2004). "Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication". J Clin Psychiatry. 65 (11): 1520–4. doi:10.4088/jcp.v65n1113. PMID 15554766.
Horst WD, Preskorn SH (December 1998). "Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion". J Affect Disord. 51 (3): 237–54. doi:10.1016/S0165-0327(98)00222-5. PMID 10333980.
Johnston AJ, Ascher J, Leadbetter R, Schmith VD, Patel DK, Durcan M, Bentley B (2002). "Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation". Drugs. 62 Suppl 2: 11–24. doi:10.2165/00003495-200262002-00002. PMID 12109932.
Xu H, Loboz KK, Gross AS, McLachlan AJ (March 2007). "Stereoselective analysis of hydroxybupropion and application to drug interaction studies". Chirality. 19 (3): 163–70. doi:10.1002/chir.20356. PMID 17167747.
Bondarev ML, Bondareva TS, Young R, Glennon RA (August 2003). "Behavioral and biochemical investigations of bupropion metabolites". Eur. J. Pharmacol. 474 (1): 85–93. doi:10.1016/S0014-2999(03)02010-7. PMID 12909199.
Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, Martin BR (September 2004). "Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors". Mol. Pharmacol. 66 (3): 675–82. doi:10.1124/mol.104.001313. PMID 15322260.
Arias HR, Santamaría A, Ali SF (2009). Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int. Rev. Neurobiol. International Review of Neurobiology. 88. hlm. 223–55. doi:10.1016/S0074-7742(09)88009-4. ISBN 9780123745040. PMID 19897080.
Warner C, Shoaib M (September 2005). "How does bupropion work as a smoking cessation aid?". Addict Biol. 10 (3): 219–31. doi:10.1080/13556210500222670. PMID 16109583.
Stahl, SM; Pradko, JF; Haight, BR; Modell, JG; Rockett, CB; Learned-Coughlin, S (2004). "A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor". Primary Care Companion to the Journal of Clinical Psychiatry. 6 (4): 159–166. doi:10.4088/PCC.v06n0403. PMC 514842 . PMID 15361919.
Meyer A, Vuorinen A, Zielinska AE, Strajhar P, Lavery GG, Schuster D, Odermatt A (September 2013). "Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1". Drug Metabolism and Disposition. 41 (9): 1671–8. doi:10.1124/dmd.113.052936. PMC 3876805 . PMID 23804523.
Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH (April 2004). "Pharmacogenetic determinants of inter-individual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes". Pharmacogenetics. 14 (4): 225–38. doi:10.1097/00008571-200404000-00002. PMID 15083067.
Weintraub D, Linder MW (2000). "Amphetamine positive toxicology screen secondary to bupropion". Depress Anxiety. 12 (1): 53–4. doi:10.1002/1520-6394(2000)12:1<53::AID-DA8>3.0.CO;2-4. PMID 10999247.
Casey, E.R.; Scott, M.G.; Tang, S.; Mullins, M.E. (Juni 2011). "Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay". J Med Toxicol. 7 (2): 105–8. doi:10.1007/s13181-010-0131-5. PMC 3724447 . PMID 21191682.
Sager JE, Choiniere JR, Chang J, Stephenson-Famy A, Nelson WL, Isoherranen N (2016). "Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans". ACS Med Chem Lett. 7 (8): 791–6. doi:10.1021/acsmedchemlett.6b00189. PMC 5026406 . PMID 27660681.
Perrine DM, Ross JT, Nervi SJ, Zimmerman RH (2000). "A Short, One-Pot Synthesis of Bupropion (Zyban, Wellbutrin)". Journal of Chemical Education. 77 (11): 1479. Bibcode:2000JChEd..77.1479P. doi:10.1021/ed077p1479.

drugs.com

"Bupropion Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. 5 Februari 2018. Diakses tanggal 15 Juli 2018.
"Bupropion Use During Pregnancy". Drugs.com (dalam bahasa Inggris). Diakses tanggal 24 Desember 2018.
"Bupropion International Brands". Drugs.com. Diakses tanggal 1 Juni 2017.

emedexpert.com

"Bupropion (Wellbutrin)". eMedExpert.com. 31 Maret 2008. Diarsipkan dari versi asli tanggal 2013-08-06. Diakses tanggal 20 Agustus 2013.

fda.gov

accessdata.fda.gov

FDA Buproprion Label Last revised 16 December 2014 as described on the FDA Label Website. Lihat situs tersebut untuk pembaruan. Halaman diakses 8 April 2016.
"Wellbutrin entry in the Orange Book". U.S. Food and Drug Administration Center for Drug Evaluation and Research. Diakses tanggal 18 August 2007.

garant.ru

base.garant.ru

"Постановление Правительства РФ от 30 июня 1998 г. N 681 "Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации" (с изменениями и дополнениями)" (dalam bahasa Rusia). Гарант. Diakses tanggal 2019-04-28. Эфедрон (меткатинон) и его производные, за исключением производных, включенных в качестве самостоятельных позиций в перечень

google.ca

books.google.ca

Dye, Leslie R.; Murphy, Christine; Calello, Diane P.; Levine, Michael D.; Skolnik, Aaron (2017). Case Studies in Medical Toxicology: From the American College of Medical Toxicology (dalam bahasa Inggris). Springer. hlm. 85. ISBN 9783319564494.

gsk.com

GlaxoSmithKline (26 Juli 2006) "Pipeline Update" (PDF). Diarsipkan dari versi asli (PDF) tanggal 27 September 2007. (136 KB). Rilis pers. Diakses pada 18 Agustus 2007.

harvard.edu

adsabs.harvard.edu

Perrine DM, Ross JT, Nervi SJ, Zimmerman RH (2000). "A Short, One-Pot Synthesis of Bupropion (Zyban, Wellbutrin)". Journal of Chemical Education. 77 (11): 1479. Bibcode:2000JChEd..77.1479P. doi:10.1021/ed077p1479.

medicaid.gov

data.medicaid.gov

"NADAC as of 2018-12-19". Centers for Medicare and Medicaid Services (dalam bahasa Inggris). Diarsipkan dari versi asli tanggal 2018-12-19. Diakses tanggal 22 December 2018.

medicines.org.uk

"Zyban 150 mg prolonged release film-coated tablets – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 1 Agustus 2013. Diakses tanggal 22 Oktober 2013.

medscape.com

Waknine, Yael (8 May 2008). "FDA Approvals: Advair, Relistor, Aplenzin". Medscape. Diakses tanggal 9 May 2008.

nih.gov

ncbi.nlm.nih.gov

Zhu, A. Z. X.; Zhou, Q.; Cox, L. S.; Ahluwalia, J. S.; Benowitz, N. L.; Tyndale, R. F. (3 September 2014). "Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes". Drug Metabolism and Disposition. 42 (11): 1971–1977. doi:10.1124/dmd.114.060285. PMC 4201132 . PMID 25187485.
Schwasinger-Schmidt, TE; Macaluso, M (8 September 2018). "Other Antidepressants". Handbook of Experimental Pharmacology. doi:10.1007/164_2018_167. PMID 30194544.
Fava M, Rush AJ, Thase ME, et al. (2005). "15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL". Prim Care Companion J Clin Psychiatry. 7 (3): 106–13. doi:10.4088/pcc.v07n0305. PMC 1163271 . PMID 16027765.
Jefferson JW, Pradko JF, Muir KT (November 2005). "Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations". Clin Ther. 27 (11): 1685–95. doi:10.1016/j.clinthera.2005.11.011. PMID 16368442.
Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT (2006). "Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent". CNS Drug Rev. 12 (3–4): 178–207. doi:10.1111/j.1527-3458.2006.00178.x. PMID 17227286.
Fidel Vila-Rodriguez, Fidel; Dobek, Christine E; Blumberger, Daniel M; Downar, Jonathan; Daskalakis, Zafiris J (2015). "Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion". Neuropsychiatric Disease and Treatment. 11: 2975–87. doi:10.2147/NDT.S91126. ISSN 1178-2021. PMC 4670017 . PMID 26664122.
Feinberg SS (2004). "Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication". J Clin Psychiatry. 65 (11): 1520–4. doi:10.4088/jcp.v65n1113. PMID 15554766.
Horst WD, Preskorn SH (December 1998). "Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion". J Affect Disord. 51 (3): 237–54. doi:10.1016/S0165-0327(98)00222-5. PMID 10333980.
Johnston AJ, Ascher J, Leadbetter R, Schmith VD, Patel DK, Durcan M, Bentley B (2002). "Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation". Drugs. 62 Suppl 2: 11–24. doi:10.2165/00003495-200262002-00002. PMID 12109932.
Xu H, Loboz KK, Gross AS, McLachlan AJ (March 2007). "Stereoselective analysis of hydroxybupropion and application to drug interaction studies". Chirality. 19 (3): 163–70. doi:10.1002/chir.20356. PMID 17167747.
Bondarev ML, Bondareva TS, Young R, Glennon RA (August 2003). "Behavioral and biochemical investigations of bupropion metabolites". Eur. J. Pharmacol. 474 (1): 85–93. doi:10.1016/S0014-2999(03)02010-7. PMID 12909199.
Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, Martin BR (September 2004). "Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors". Mol. Pharmacol. 66 (3): 675–82. doi:10.1124/mol.104.001313. PMID 15322260.
Arias HR, Santamaría A, Ali SF (2009). Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int. Rev. Neurobiol. International Review of Neurobiology. 88. hlm. 223–55. doi:10.1016/S0074-7742(09)88009-4. ISBN 9780123745040. PMID 19897080.
Warner C, Shoaib M (September 2005). "How does bupropion work as a smoking cessation aid?". Addict Biol. 10 (3): 219–31. doi:10.1080/13556210500222670. PMID 16109583.
Ascher JA, Cole JO, Colin JN, et al. (September 1995). "Bupropion: a review of its mechanism of antidepressant activity". J Clin Psychiatry. 56 (9): 395–401. PMID 7665537.
Stahl, SM; Pradko, JF; Haight, BR; Modell, JG; Rockett, CB; Learned-Coughlin, S (2004). "A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor". Primary Care Companion to the Journal of Clinical Psychiatry. 6 (4): 159–166. doi:10.4088/PCC.v06n0403. PMC 514842 . PMID 15361919.
Ascher, JA; Cole, JO; Colin, JN; Feighner, JP; Ferris, RM; Fibiger, HC; Golden, RN; Martin, P; Potter, WZ; Richelson, E (September 1995). "Bupropion: a review of its mechanism of antidepressant activity". The Journal of Clinical Psychiatry. 56 (9): 395–401. PMID 7665537.
Meyer A, Vuorinen A, Zielinska AE, Strajhar P, Lavery GG, Schuster D, Odermatt A (September 2013). "Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1". Drug Metabolism and Disposition. 41 (9): 1671–8. doi:10.1124/dmd.113.052936. PMC 3876805 . PMID 23804523.
Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH (April 2004). "Pharmacogenetic determinants of inter-individual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes". Pharmacogenetics. 14 (4): 225–38. doi:10.1097/00008571-200404000-00002. PMID 15083067.
Preskorn SH (1991). "Should bupropion dosage be adjusted based upon therapeutic drug monitoring?". Psychopharmacol Bull. 27 (4): 637–43. PMID 1813908.
Weintraub D, Linder MW (2000). "Amphetamine positive toxicology screen secondary to bupropion". Depress Anxiety. 12 (1): 53–4. doi:10.1002/1520-6394(2000)12:1<53::AID-DA8>3.0.CO;2-4. PMID 10999247.
Nixon AL, Long WH, Puopolo PR, Flood JG (Juni 1995). "Bupropion metabolites produce false-positive urine amphetamine results". Clin. Chem. 41 (6 Pt 1): 955–6. PMID 7768026.
Casey, E.R.; Scott, M.G.; Tang, S.; Mullins, M.E. (Juni 2011). "Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay". J Med Toxicol. 7 (2): 105–8. doi:10.1007/s13181-010-0131-5. PMC 3724447 . PMID 21191682.
Sager JE, Choiniere JR, Chang J, Stephenson-Famy A, Nelson WL, Isoherranen N (2016). "Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans". ACS Med Chem Lett. 7 (8): 791–6. doi:10.1021/acsmedchemlett.6b00189. PMC 5026406 . PMID 27660681.

pubchem.ncbi.nlm.nih.gov

"Compound Summary". Bupropion. PubChem Compound. United States National Library of Medicine – National Center for Biotechnology Information. 28 Juli 2018. Diakses tanggal 29 Juli 2018.

nytimes.com

Thomas K, Schmidt MS (2 Juli 2012). "Glaxo agrees to pay $3 billion in fraud settlement". The New York Times.

tga.gov.au

ebs.tga.gov.au

"Prexaton Bupropion hydrochloride PRODUCT INFORMATION". TGA eBusiness Services. Ascent Pharma Pty Ltd. 2 Oktober 2012. Diakses tanggal 22 Oktober 2013.

uspto.gov

patft.uspto.gov

Mehta NB (25 Juni 1974). "United States Patent 3,819,706: Meta-chloro substituted α-butylamino-propiophenones". USPTO. Diarsipkan dari versi asli tanggal 2017-11-07. Diakses tanggal 2 Juni 2008.

web.archive.org

Mehta NB (25 Juni 1974). "United States Patent 3,819,706: Meta-chloro substituted α-butylamino-propiophenones". USPTO. Diarsipkan dari versi asli tanggal 2017-11-07. Diakses tanggal 2 Juni 2008.
World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83" (PDF). WHO Drug Information. 14 (2). Diarsipkan dari versi asli (PDF) tanggal 1 February 2010. Diakses tanggal 22 June 2009.
"NADAC as of 2018-12-19". Centers for Medicare and Medicaid Services (dalam bahasa Inggris). Diarsipkan dari versi asli tanggal 2018-12-19. Diakses tanggal 22 December 2018.
"GlaxoSmithKline (GSK) Reviews Novel Therapeutics For CNS Disorders And Confirms Strong Pipeline Momentum" (Siaran pers). PRNewswire. 23 November 2004. Diarsipkan dari versi asli tanggal 28 September 2007. Diakses tanggal 18 August 2007. "Salinan arsip". Diarsipkan dari versi asli tanggal 2017-03-20. Diakses tanggal 2019-07-07.
GlaxoSmithKline (26 Juli 2006) "Pipeline Update" (PDF). Diarsipkan dari versi asli (PDF) tanggal 27 September 2007. (136 KB). Rilis pers. Diakses pada 18 Agustus 2007.
"Bupropion (Wellbutrin)". eMedExpert.com. 31 Maret 2008. Diarsipkan dari versi asli tanggal 2013-08-06. Diakses tanggal 20 Agustus 2013.

worldcat.org

Fidel Vila-Rodriguez, Fidel; Dobek, Christine E; Blumberger, Daniel M; Downar, Jonathan; Daskalakis, Zafiris J (2015). "Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion". Neuropsychiatric Disease and Treatment. 11: 2975–87. doi:10.2147/NDT.S91126. ISSN 1178-2021. PMC 4670017 . PMID 26664122.